Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease

LettersSeptember 2021Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune DiseaseMonique K. van der Kooij, MD, Karijn P.M. Suijkerbuijk, MD, PhD, Olaf M. Dekkers, MD, PhD, Ellen Kapiteijn, MD, PhDMonique K. van der Kooij, MD, Karijn P.M. Suijkerbuijk, MD, PhD, Olaf M. Dekkers, MD, PhD, Ellen Kapiteijn, MD, PhDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L21-0442 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE: We thank Dr. Yang and colleagues for their interest in our article and would like to respond to the concerns that they raised.First, Dr. Yang and colleagues contend that the prevalence and severity of immune-related adverse events would have differed if we had excluded patients with preexisting thyroid disorders. They refer to a phase 1b trial in which—as in most currently recruiting checkpoint inhibitor trials—thyroid disorders are not an exclusion criterion. Because our aim was to include all autoimmune disorders, we explicitly included both hypo- and hyperthyroidism. However, in Appendix Tables 5 to 7 of our article, ... Author, Article, and Disclosure InformationAffiliations: Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-3419. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSafety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease Monique K. van der Kooij , Karijn P.M. Suijkerbuijk , Maureen J.B. Aarts , Franchette W.P.J. van den Berkmortel , Christian U. Blank , Marye J. Boers-Sonderen , Jesper van Breeschoten , Alfonsus J.M. van den Eertwegh , Jan Willem B. de Groot , John B.A.G. Haanen , Geke A.P. Hospers , Djura Piersma , Rozemarijn S. van Rijn , Albert J. ten Tije , Astrid A.M. van der Veldt , Gerard Vreugdenhil , Michiel C.T. van Zeijl , Michel W.J.M Wouters , Olaf M. Dekkers , and Ellen Kapiteijn Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease Xi Yang , Lilit Karapetyan , and John M. Kirkwood Metrics September 2021Volume 174, Issue 9Page: 1345-1346 ePublished: 21 September 2021 Issue Published: September 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...